Botkin.AI Medical Image Analysis and Processing Platform with AI Technologies

The main articles are:

• Neural networks (neural networks)
• Artificial Intelligence in Medicine
• Artificial intelligence in radiology

Botkin.AI medical is an image analysis platform for detecting pathologies using technology. artificial intelligence The product is easily integrated medical software with and equipment in any clinic. The implementation of the platform increases the effectiveness of medical diagnostics, reduces the risk of missing pathologies, reduces the burden on doctors. radiologists

The main users of the platform are public and private medical institutions, health authorities, pharmaceutical companies, contract research organizations, insurance companies.

The Scientific Advisory Medical Council is headed by the President of the Russian Society of Radiologists and Radiologists, Professor Valentin Evgenievich Sinitsyn.

The Botkin.AI platform offers the following products:

• Analysis of medical images, including:
  • CT
  • mammography tests
  • radiographs

• Teleradiology - remote description of medical images, routing of research, quality control of diagnostics

(data current as of December 2021)

2023: Suspension of application by Roszdravnadzor

Roszdravnadzor for the first time suspended the use of the Botkin.AI medical system with artificial intelligence (AI) due to the threat of harm to life and health of people. This was reported in the department on November 21, 2023.

During the monitoring of the safety of medical devices conducted by Roszdravnadzor in relation to Botkin.AI, deviations in the characteristics (results of the software with AI) were revealed relative to those declared during its state registration. As a result of the analysis, Roszdravnadzor concluded that there is a threat of harm to the life and health of citizens when using Botkin.AI. In this regard, a decision was made to suspend its application, and an unscheduled selective control was initiated against the manufacturer Botkin.AI Intellectojik LLC, the service's Telegram channel says.

Screenshot from Botkin.AI

It also noted that AI products in Russia are subject to post-registration monitoring of safety and clinical effectiveness, reports on which are analyzed by Roszdravnadzor. Despite the repeated demands of Roszdravnadzor, the specified reports from the manufacturer Botkin.AI were not received by the department.

In November 2023, the Moscow Department of Health told Kommersant that Botkin.AI is not used in urban clinics. At the same time, AI services have been introduced into the Moscow health care system, which are used as part of an experiment in 28 clinical areas. It is the medical image analysis system of Celsus, the Third Opinion platform, AIDiagnostic. In total, 50 such services are used, added to the Department of Health.

According to the head of Medleveltech, Mikhail Vinogradov, AI solutions belong to a high, third class of risk, so Roszdravnadzor pays such close attention to them.^[1]

2021: Obtaining a CE Mark European Certificate

Intellojik, a resident of the Skolkovo Foundation's Biomedical Technology Cluster, has received CE Mark European certification for the Botkin.AI software platform for analyzing medical research using artificial intelligence technologies. The Skolkovo Foundation announced this on February 2, 2021.

According to the obtained international CE Mark certificate, the Botkin.AI platform can be used in medical practice to visualize and accompany screening studies, ensure quality control of the description of medical diagnostic studies in the field of radiology, including CT, X-ray and mammography analysis.

The company will soon announce the launch of a number of international projects using the Botkin.AI platform. Obtaining CE Mark certification opens up great prospects for the industrial use of Botkin.AI in the daily workflow of physicians, both in Europe and in many countries around the world. To expand the geography of projects, the company also plans to obtain an American FDA certificate.

Obtaining CE Mark was an important part of our development strategy. The process, both the preparation of application documents and the passage of all stages of verification, took a long time and required serious preparation from our team. It is also important for us to show our valued customers in Russia and abroad that our product meets all strict quality standards. With European certification, we plan large-scale development, both in Europe and abroad, not forgetting, of course, about the implementation of successful projects in Russia. said Sergey Sorokin, CEO of Intellozhik

The Botkin.AI platform is an integrated IT and AI product that allows not only to analyze research using artificial intelligence technologies, but also to visualize the results obtained using its own viewer, as well as manage research flows. The platform has its own proprietary technologies for creating, updating and managing mathematical models for the analysis of medical information.

Obtaining an international certificate will expand the geography of using a Russian certified software product with artificial intelligence and meets the development strategy of Botkin.AI as a comprehensive international medical platform with artificial intelligence.

The Botkin.AI platform of the Skolkovo resident of the Intellectojik company has become a decision from Russia, which has received the approval of the European regulator in the direction of the use of AI in healthcare. This permission allows you to fully export Botkin.AI to the EU countries . It is worth noting that the CE Mark confirms the high level of the developed platform on a global scale. The Skolkovo Foundation has supported Intellojik for more than three years, almost from the moment the company was founded, and we are glad to see its rapid development with such excellent results. noted Sergey Voinov, Head of Digital Health of the Skolkovo Foundation Biomedical Technology Cluster

2020

Obtaining Roszdravnadzor marketing authorization

The Intellectodzhik company, a resident of the Skolkovo Foundation Biomedical Technology Cluster, received the first registration certificate (RU) of Roszdravnadzor in Russia for software for analyzing medical images using artificial intelligence. The Skolkovo Foundation announced this on November 6, 2020. The RA is issued by risk class 2b, which allows the use of the Botkin.AI platform in medical organizations in diagnostic processes, including for the diagnosis of diseases with a high health risk.

The Botkin.AI platform is registered as a medical device and can be used to manage, process, monitor, obtain and display a large number of medical images of the following types and pathologies:

Roszdravnadzor registered the first AI platform for the analysis of medical records

• CT studies, including malignant neoplasms and syndromes associated with COVID-19;
• X-rays, including tuberculosis, malignant neoplasms, pneumonia;
• mammography, including for breast cancer screening.

The Botkin.AI platform includes both mathematical models for analyzing medical images using artificial intelligence technologies, as well as professional tools for the work of radiologists, as well as tools for integration with medical information systems.

Clinical trials of the Botkin.AI platform were carried out on the basis of the Central Clinical Hospital of the Russian Academy of Sciences.

Obtaining a marketing authorization from Roszdravnadzor is a big and important step in the development of our platform. We are confident that the procedure for obtaining a RU is an important and necessary stage for all developers of software with artificial intelligence, ensuring the safe use of these technologies in clinics. Obtaining a RA will open up opportunities for using our platform in regional screening programs within the framework of the national project "Health," to improve the effectiveness of the fight against the COVID-19 pandemic, to improve the effectiveness of radiologists in public and private medical organizations. The next step in the development of our platform is to obtain international certification in the near future.

Botkin.AI is based on a patented technology for creating mathematical models for analyzing medical data. It allows you to achieve some of the best indicators in the world in the accuracy of the analysis of medical images. The Skolkovo Foundation in time supported the Intellect team with a Botkin.AI development and testing grant. And the long-awaited marketing authorization finally opens up the possibility for full-fledged, legitimate platform implementations. The risk class 2b of the medical certificate will allow to analyze with the help of Botkin.AI the spectrum of all types of medical images and pathologies. This will reduce the burden on radiologists, improve the quality of their work and help save human lives.

ERIS Moscow launched a program for recognizing lung cancer by CT scans

In the unified radiological system of Moscow, the Botkin.AI CT scan lung cancer recognition program has been launched. This platform, developed by Intellojik, will analyze images taken in 46 capital medical institutions. Read more here.

Scaling with the Mail.ru Cloud

On April 17, 2020, it became known that the Botkin.AI platform will help reduce the burden on doctors during the spread COVID-19 and reduce the likelihood of medical errors. With the help of technology artificial intelligence , it detects and marks in lung images signs of pneumonia, which is a symptom of a severe course of the disease. Mail.ru Cloud Solutions will provide to the developer cloudy servers to scale the project. More. here

Addition of pneumonia analysis functionality and provision of temporary free stupa

On March 25, 2020, the Skolkovo Foundation announced that its resident, the Russian company Intellectojik, promptly developed and added functionality for analyzing pneumonia to the Botkin.AI platform. The company expects that this will reduce the risks and mitigate the possible consequences of the COVID-19 coronavirus epidemic.

Botkin.AI

Botkin.AI is a platform for the analysis and processing of medical images using artificial intelligence. Due to the difficult epidemiological situation and the need to take operational measures, the company has opened free access to the emerging platform functionality for all medical organizations involved in the diagnosis and treatment of patients with COVID-19.

One of the first pilot projects to use this platform functionality will start in the Yamalo-Nenets Autonomous Okrug. They will test the updated Botkin.AI product in order to reduce the risks of missing signs of coronavirus pneumonia. In the future, the product can be used to control the dynamics of the course of pneumonia, including in patients with coronavirus COVID-19. In the near future, it is planned to start similar projects in other regions of Russia.

Our company pays great attention scientific to the research and development of products for health care using artificial intelligence technologies. We are very pleased that the work done has helped us to launch an important project to reduce the risks and possible consequences of the COVID-19 coronavirus epidemic as soon as possible. We look forward to the positive results of its testing in practical healthcare and are ready to launch similar projects in other regions of Russia as soon as possible. Due to the difficult epidemiological situation, we provide access to the functionality of our platform for free until May 2020. We hope that our developments will help doctors, and most importantly, will benefit patients, said Sergey Sorokin, CEO of Intellozhik (Botkin.AI project):

The question of the increased burden on the health care system is especially acute, we provide comprehensive support to our residents who offer effective solutions for differential diagnosis of pneumonia, thus increasing the speed and quality of the diagnostic process in extreme working conditions of medical organizations. It is worth noting that such systems were also used in the Chinese practice of combating the epidemic. It is especially worth noting the social responsibility of the company "Intellect," which is ready to provide its technological developments for the needs of the Russian health care system free of charge during the COVID-19 pandemic, noted Natalia Polushkina, Vice President, Executive Director of the Skolkovo Foundation Biomedical Technology Cluster

Experience in studying the development of the coronavirus epidemic shows that computed tomography and X-ray are the most important methods of comprehensive diagnosis of coronarovirus infection. Severe cases of coronavirus and deaths from it are associated with the development of viral and bacterial (secondary) pneumonia in patients, so these methods have become widely used in patients with suspected coronavirus infection and suspected lung lesions caused by the virus. The results of the examination play a crucial role in the tactics of managing and timely treatment of patients, as a result, the burden on radiologists in medical institutions increases significantly.

2019: Attracting 100 million rubles from a group of investors

The Intellect company, which develops the Botkin.AI project, has raised 100 million rubles. from the funds Digital Evolution Ventures (created with the participation of Rosatom) and RBV Capital (founded by R-Pharm Alexei Repik and the Russian venture capital company), as well as current investors - Primer Capital and ExpoCapital. Read more here.

2018: Platform Description

According to information for 2018, TeleMD Botkin.AI is a platform for diagnosing and assessing the risks of disease development using artificial intelligence technologies. The platform is based on patented technology to create mathematical models of patient representation based on various medical data: biomedical images, structured data from electronic medical records, unstructured medical information.

The Botkin.AI project will help identify oncology in the early stages, predict the risks of developing diseases and even predict the moment when the patient will see a doctor. The technology developed by the company will also monitor compliance with clinical guidelines and reduce the cost of clinical trials. As a consequence, improve the efficiency of the health care system as a whole.

The main users of the platform are clinics, health authorities, pharmaceutical companies, contract research organizations, insurance companies.

It is planned that the Botkin.AI platform will offer the following products:

• Analysis and recognition of diagnostic images, including:
  • and CT MRI
  • mammography tests
  • radiographs
  • fluorographic images

• Medical decision support systems, including:
  • diagnosis and assessment of disease risks based on analysis of medical information (electronic medical records, test results and other information)
  • monitoring the treatment process and identifying errors

• Pre-screening of patients for clinical trials

Notes